Cargando…

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nasal and paranasal sinuses. Dupilumab is a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, which are key and central drivers of type 2 inflamma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddiqui, Shahid, Bachert, Claus, Chaker, Adam M., Han, Joseph K., Hellings, Peter W., Peters, Anju T., Heffler, Enrico, Kamat, Siddhesh, Zhang, Haixin, Nash, Scott, Khan, Asif H., De Prado Gomez, Lucia, Jacob-Nara, Juby A., Rowe, Paul J., Deniz, Yamo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Study Protocols
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703146/ https://www.ncbi.nlm.nih.gov/pubmed/36451848 http://dx.doi.org/10.1183/23120541.00085-2022

Ejemplares similares

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
por: Busse, William Walter, et al.
Publicado: (2023)

Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials
por: Peters, Anju T., et al.
Publicado: (2022)

Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
por: Hopkins, Claire, et al.
Publicado: (2022)

Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps
por: Gevaert, Philippe, et al.
Publicado: (2023)

Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
por: Maspero, Jorge F, et al.
Publicado: (2023)

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
por: Hopkins, Claire, et al.
Publicado: (2021)

The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
por: Fujieda, Shigeharu, et al.
Publicado: (2020)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
por: Fujieda, Shigeharu, et al.
Publicado: (2021)

COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab
por: Förster-Ruhrmann, Ulrike, et al.
Publicado: (2020)

Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis
por: Han, Joseph K., et al.
Publicado: (2021)

Dupilumab besitzt einen Zusatznutzen für die Behandlung der chronischen Rhinosinusitis mit Nasenpolypen
por: Klimek, L., et al.
Publicado: (2021)

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
por: Domingo, Christian, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
por: Bleecker, Eugene R., et al.
Publicado: (2023)

Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
por: Bachert, Claus, et al.
Publicado: (2023)

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)
por: Rabe, Klaus F., et al.
Publicado: (2022)

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
por: Fiocchi, Alessandro G., et al.
Publicado: (2023)

Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date
por: Kim, Jean, et al.
Publicado: (2020)

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
por: Papi, Alberto, et al.
Publicado: (2022)

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
por: Hanania, Nicola A, et al.
Publicado: (2022)

Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review
por: Nitro, Letizia, et al.
Publicado: (2022)

Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps
por: Bachert, Claus, et al.
Publicado: (2021)

Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry
por: Gall, Rebecca, et al.
Publicado: (2023)

WITHDRAWN: Dupilumab: A review of potential in the treatment of Chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Sree Sudha, T.Y., et al.
Publicado: (2020)

Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab
por: Bertlich, Mattis, et al.
Publicado: (2021)

Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps
por: Kilty, Shaun J., et al.
Publicado: (2022)

Efficacy of Dupilumab in Concomitant Atopic Dermatitis and Chronic Rhinosinusitis With Nasal Polyps: A Preliminary Study
por: Nettis, Eustachio, et al.
Publicado: (2020)

Cost–Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy
por: De Corso, Eugenio, et al.
Publicado: (2022)

Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps
por: van der Lans, Rik Johannes Leonardus, et al.
Publicado: (2021)

Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
por: Al-Ahmad, Mona, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
por: Chuang, Chien‐Chia, et al.
Publicado: (2021)

Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art
por: Ren, Lei, et al.
Publicado: (2019)

Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps
por: Kariyawasam, Harsha H, et al.
Publicado: (2020)

Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care
por: Galletti, Cosimo, et al.
Publicado: (2023)

The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps
por: Patel, Gayatri B., et al.
Publicado: (2020)

Development of Sinonasal Outcome Test (SNOT‐22) Domains in Chronic Rhinosinusitis With Nasal Polyps
por: Khan, Asif H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_df26pf52ts2h79qcub3fq7fdrq